3Cutts C, LaCaze A, Tett S. A clinical audit of the prescribing of celecoxb and rofecoxib in Australian rural general practice. Br J Clin Pharmaco1,2002 ,54 :522-527.
二级参考文献10
1Choo KS, Kim IW,Jung JK, et al. Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC- UV detection method[J]. J Pharm Biomed Anal ,2001,25(3 - 4) :639 - 650.
2Kim IW, Choo KS, Han TG, et al. Decreased oral bioavailability of loxoprofen at second administration in htmaan subjects[J]. Int J Clin Pharmacol Ther ,2000,38( 1 ) : 10 - 14.
3Hirai T, Matsumoto S, Kishi I. Simultaneous analyds of several nonsteroidal anti-inflammatory drugs hn human urine by high-performance liquid chromatography with normal solid-phase extraction[J].J Chromatogr B Biomed Sci Appl, 1997,692 (2) : 375 - 388.
4Van der LS,Valkenburg H,Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria[J]. Arthritis Rheum, 1984,27: 361-368.
5Anderson J, Baron G, van der Heijde D, et al. ASAS preliminary criteria for short term improvement in ankylosing spondylitis[J].Arthritis Rheum ,2001,44:1876-1886.
6Calin A,Garrett S,Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index(BASFI)[J].J Rheumatol, 1994,21:2281-2285.
7Garrett S, J enkinson T, Whitelock H, et al. A new approach to defining disease status in AS:the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)[J].J Rheumatol, 1994,21: 2286-2291.
8Yanagawa A,Fukumura T,Matsui H, et al. Possible Mechanisms of gastroduodenal mucosal damage in volunteers Treated with NSAIDs: The usefulness of prodrugs[J].J Rheumatol, 1992,19:1075-1082.
5Aronson JK. Meyler's side effects O: drugs: the interna- tional encyclopedia of adverse drug reactions and Interac- tions[ M]. 15th ed. Amsterdam: Elsevier Science Pub- lishers B. V. , 2006: 2173.
10Turk BG, Gunaydin A, Ertam I, et al. Adverse cutaneous drug reactions among hospitalized patients : five year surveillance [ J ]. Cutan Ocul Toxicol, 2013,32:41-45.
